(Q54611393)

1 June 2018

title

A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis. (English)

1 reference

1 June 2018

myeloproliferative disorders

main subject

1 reference

5

1 reference

1 June 2018

author name string

Vannucchi AM

1

1 reference

1 June 2018

Pancrazzi A

2

1 reference

1 June 2018

Bogani C

3

1 reference

1 June 2018

Antonioli E

4

1 reference

1 June 2018

publication date

1 June 2006

1 reference

1 June 2018

published in

Leukemia

1 reference

1 June 2018

volume

20

1 reference

1 June 2018

issue

6

1 reference

1 June 2018

page(s)

1055-1060

1 reference

1 June 2018

https://scigraph.springernature.com/pub.10.1038/sj.leu.2404209

exact match

0 references

cites work

Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404209

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404209

Diagnosis of the myeloproliferative disorders: resolving phenotypic mimicry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404209

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404209

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404209

A gain-of-function mutation of JAK2 in myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404209

Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404209

Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404209

The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404209

JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404209

Clinical implications of the JAK2 V617F mutation in essential thrombocythemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404209

JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404209

The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404209

V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404209

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404209

Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404209

The World Health Organization (WHO) classification of the myeloid neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404209

The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404209

An efficient procedure for genotyping single nucleotide polymorphisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404209

PRV-1, erythroid colonies and platelet Mpl are unrelated to thrombosis in essential thrombocythaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404209

Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404209

inferred from DOI database lookup

7 January 2021

based on heuristic

Inconsistencies in the association between the JAK2V617F mutation and PRV-1 over-expression among the chronic myeloproliferative diseases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404209

inferred from DOI database lookup

7 January 2021

based on heuristic

Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404209

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.LEU.2404209

1 reference

1 June 2018

1 reference

1 June 2018